zintick

FATE Therapeutics FATE

Fate Therapeutics Inc · Nasdaq · Biological Products, (No Diagnostic Substances)

$1.34-16.77%close on Nov. 12, 2026 · volume 3.7M · Yahoo Finance

Price, last 58 sessions

$1.50$2.00$2.50Sept. 2026Oct. 2026Nov. 2026
Aug. 24, 2026 to Nov. 12, 2026 · high $2.58 · low $1.34 · SEC filing, placed when SEC released it

Our coverage

Nothing published yet.

Insider buying and selling

DateInsiderTradeSharesAvg. priceValue
Nov. 3, 2026Kamal Adawi
Chief Financial Officer
Sold6,582$2.05$13,525
Aug. 4, 2026Cindy Tahl
See Remarks
Sold38,800$2.46$95,405
Aug. 4, 2026Bahram Valamehr
President and CEO, director
Sold43,947$2.46$108,101

Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.

Recent SEC filings

All 12 →
  • 424B5Nov. 12, 2026, 5:21 p.m. ETView on SEC.gov
  • SCHEDULE 13D/ANov. 9, 2026, 7:08 p.m. ETView on SEC.gov
  • 424B5Nov. 5, 2026, 4:36 p.m. ETView on SEC.gov
  • 8-KNov. 5, 2026, 4:11 p.m. ETView on SEC.gov

    Entry into a material definitive agreement · Termination of a material definitive agreement · Financial statements and exhibits

    AI summary, unreviewedFate Therapeutics Enters $100.0 Million At-the-Market Stock Sale Agreement With Leerink Partners, Terminates Jefferies ATM

  • 10-QNov. 5, 2026, 7:07 a.m. ETView on SEC.gov
  • 8-KNov. 5, 2026, 7:04 a.m. ETView on SEC.gov

    Results of operations and financial condition · Financial statements and exhibits

    AI summary, unreviewedFate Therapeutics Q3 2026 EPS of -$0.25 Beats $0.26 Loss Estimate, but Revenue Falls to Zero; Cash Declines to $139.1 Million

  • 4Nov. 4, 2026, 4:01 p.m. ETView on SEC.gov
  • 8-KSept. 28, 2026, 8:10 a.m. ETView on SEC.gov

    Other events · Financial statements and exhibits